Aptadir closed a €40 million seed round to advance its RNA therapeutics pipeline, including a lead candidate for Fragile X Syndrome.
- Amount
- $45.4M
- Stage
- Seed
- Announced
- 29 September 2026
- Lead
- 4BIO Capital
- Other investors
- EXTEND, CDP Venture Capital SGR, Angelini Ventures, Evotec SE, CDP Venture Capital, Indaco Venture Partners, XGEN Venture, CE-Ventures, Kerna Ventures, Italian Angels for Biotech, Club degli Investitori
- Use of funds
- Advance the company's pipeline of disease-modifying investigational RNA therapeutics, including lead candidate CAP1-FMR1 for Fragile X Syndrome.
- Checked
- Announced by the company